NCT05002361

Brief Summary

This explorative post hoc analysis included patients randomized in the DEX-2-TKA trial (NCT03506789) who were operated under general anesthesia with remifentanil and propofol. Patients having general anesthesia with sevoflurane were excluded. As the two groups receiving preoperative dexamethasone were identical at the time of outcome assessment, they were merged to one and were compared with placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
94

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Sep 2018

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 14, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 7, 2020

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

July 13, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 12, 2021

Completed
Last Updated

August 12, 2021

Status Verified

August 1, 2021

Enrollment Period

1.5 years

First QC Date

July 13, 2021

Last Update Submit

August 11, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Intraoperative use of remifentanil

    mg

    During surgery (from surgical incision till last suture)

Secondary Outcomes (3)

  • Intraoperative use of propofol

    During surgery (from surgical incision till last suture)

  • Anesthesia depth

    During surgery (from surgical incision till last suture)

  • Time in post-anesthesia care unit (PACU)

    Time at the PACU (from arrival at the PACU untill transfer to orthopedic ward), approximated 0-4 hours

Study Arms (2)

Treatment A+B

ACTIVE COMPARATOR

24 mg dexamethasone i.v. perioperatively

Drug: Dexamethasone

Placebo

PLACEBO COMPARATOR

Placebo (isotonic saline) i.v. perioperatively

Drug: Isotonic saline

Interventions

24 mg intravenous Dexamethasone (6 ml)

Treatment A+B

6 ml of isotonic saline

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participation in DEX-2-TKA (NCT03506789)
  • General anesthesia

You may not qualify if:

  • Spinal anestehesia
  • Use of sevoflurane

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Gildhøj Privathospital

Brøndby, 2605, Denmark

Location

Bispebjerg Hospital

Copenhagen, 2400, Denmark

Location

Sjællands Universitetshospital, Køge

Køge, 4600, Denmark

Location

Næstsved Sygehus

Næstved, 4700, Denmark

Location

Odense Universitetshospital

Odense, 5000, Denmark

Location

Related Publications (1)

  • Gantzel M, Gasbjerg KS, Hagi-Pedersen D, Meyhoff CS, Olsen MH, Mathiesen O, Jakobsen JC, Lunn TH. Effect of dexamethasone on intraoperative remifentanil dose in total knee arthroplasty surgery under general anaesthesia. Acta Anaesthesiol Scand. 2022 Oct;66(9):1070-1076. doi: 10.1111/aas.14118. Epub 2022 Aug 4.

MeSH Terms

Interventions

DexamethasoneSodium Chloride

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Kasper S Gasbjerg, MD

    Naestved Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 13, 2021

First Posted

August 12, 2021

Study Start

September 14, 2018

Primary Completion

March 11, 2020

Study Completion

June 7, 2020

Last Updated

August 12, 2021

Record last verified: 2021-08

Locations